chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Joint Pain in Fingers; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ARTHRALGIA (non-serious), outcome "unknown", described as "Joint Pain in Fingers".  Additional information: The reporter was reporting on Adverse Events for herself and during the supplemental form questions mentioned Adverse Events for her Brother.  Family Medical History Relevant to AE(s): Mom and Brother also got Joint Pain in Fingers but no neurological issues. Not sure on details. Dates, NDC, Lot, Expiration Unknown. Declines to complete a full report at this time.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Shinglesincluding any and all of its sequelae; Information has been received on 30-MAY-2019 from a lawyer regarding a case in litigation, concerning a 64-year-old male patient (pt). There was no information provided regarding the pt's concurrent conditions, medical history or concomitant medications. On 17-JAN-2015, the pt was inoculated with Zoster Vaccine Live (ZOSTAVAX) (lot number, expiration date, dose and route of administration unknown) for prophylaxis. On 29-MAY-2016, the pt was caused to suffer Shingles, including any and all of its sequelae. The pt was caused to suffer severe personal injuries, pain, suffering, and emotional distress, as well as to incur substantial economic damages. As a foreseeable, direct, and proximate consequence of zoster vaccine live (ZOSTAVAX), the pt suffered Shingles and other related health complications. In addition, the pt requires and will continue to require healthcare and services. The patient has incurred and will continue to incur medical and related expenses, also has suffered and will continue to suffer diminished capacity for the enjoyment of life, a diminished quality of life, increased risk of premature death, aggravation of preexisting conditions, activation of latent conditions, and other losses and damages. The pt's direct medical losses and costs include physician care, monitoring, and treatment. The pt has incurred and will continue to incur mental and physical pain and suffering. The outcome of the event is not recovered. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).
Dizziness, light-headedness, nausea, dry mouth, metallic taste, tingly tongue and mouth, heart palpitations and anxiety within 10 minutes of the shot.
Patient was immunized with vaccine that has beyond-use-date (BUD) of 7/15/22; MFG: 11/2021; EXP: 10/31/22. No temperature excursion during this time period. We have reached out to Pfizer for additional information regarding the vaccine viability past the Beyond Use Date, currently waiting on response.
Red rash on left upper arm- not painful or itchy.  Resolved in 24 hours.
Expired Havrix administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a patient who received HAV (Havrix) (batch number unknown, expiry date 9th September 2022) for prophylaxis.   On 16th September 2022, the patient received Havrix. On 16th September 2022, unknown after receiving Havrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 21 September 2022 Reporter's comment: Health care professional reported an expired dose of Havrix was administered to a patient. Expired on 9th September 2022. Reporter did not consent to follow. Additional Supportive Information: The patient received expired dose of Havrix, which led to expired vaccine used.
shortness of breath; aching on the left side of the chest; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported), via an unspecified route of administration on 21Jan2021 as single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced shortness of breath, aching on the left side of the chest for a week in Jan2021 with outcome of not recovered. The patient was wondering whether it was okay to get the second dose as scheduled on 11Feb2021.  Information on the lot/batch number has been requested.
Patient received a sub-optimal COVID-19 vaccine due to a storage and handling error. Vaccine stored in a regular freezer prior to being refrigerated, then administered. CDC requested a VAERS form be submitted for this patient.
02/02/22 presents to ED for "shortness of breath". PMHx of "CHF"
periorbital edema bilat, no drainage from nose, lungs clear to auscultation bilat, no wheeze, no fever or cough, HRR, epi given ? swollen but no breaking, minimal inflammed TM;DPH given, SOlumedrol given;
FEELING CRANKY; RASH/HIVES ON THE BODY; EXTRA TIREDNESS; This spontaneous report received from a patient concerned a 58 year old female. The patient's height, and weight were not reported. The patient's past medical history included chicken pox, and concurrent conditions included sulpha drug allergy, and other pre-existing medical conditions included on hormone replacement therapy for a long time progesterone and estradiol on some longstanding otc's, sulpha drug allergy.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808609, and batch number: 1808609 expiry: UNKNOWN) dose was not reported, administered on 25-MAR-2021 for prophylactic vaccination. Concomitant medications included estradiol for hormone replacement therapy, and progesterone for hormone replacement therapy. On an unspecified date, the subject experienced feeling cranky, rash/hives on the body, and extra tiredness. Treatment medications (dates unspecified) included: camphor, menthol, loratadine, and pramocaine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the rash/hives on the body, extra tiredness and feeling cranky was not reported. This report was non-serious.
Pt. died 2 days after receiving vaccines. Autopsy resutls pending. Specimens to be sent to CDC for testing. Autopsy report received on 2/12/2003 indicates overdose.
Rash and swelling at injection site. Injection site pain. Nausea. Coughing. Sneezing. All over body aches/pains.
dizziness, ear fullness in both ears, headaches. Still experiencing these same symptoms at 6 weeks post shot
Vaccine expired on 03-Oct-2021/ refrigerated on 04-Nov-2021/ administered on 03-Dec-2021; Doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses were given after expiration date) and PRODUCT STORAGE ERROR (Vaccine expired on 03-Oct-2021/ refrigerated on 04-Nov-2021/ administered on 03-Dec-2021) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses were given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine expired on 03-Oct-2021/ refrigerated on 04-Nov-2021/ administered on 03-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Doses were given after expiration date) and PRODUCT STORAGE ERROR (Vaccine expired on 03-Oct-2021/ refrigerated on 04-Nov-2021/ administered on 03-Dec-2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The healthcare professional (HCP) wanted to know about the protocol for this situation and whether the doses were viable or not. HCP said that there was a confusion between the expiration date printed in the carton and the expiration date when the QR code is scanned.  There was no temperature excursion and the patient did not experienced any adverse event.  The vaccine was place in the refrigerator on 04-Nov-2021.  No treatment medications were reported.
Numbness on the left side of her face; Metallic taste in her mouth; Dizziness; Flu-like symptoms; Got super sick; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), INFLUENZA LIKE ILLNESS (Flu-like symptoms), ILLNESS (Got super sick) and HYPOAESTHESIA (Numbness on the left side of her face) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, the patient experienced DIZZINESS (Dizziness), INFLUENZA LIKE ILLNESS (Flu-like symptoms) and ILLNESS (Got super sick). On 04-Feb-2021, the patient experienced HYPOAESTHESIA (Numbness on the left side of her face). On 04-Feb-2021, HYPOAESTHESIA (Numbness on the left side of her face) had resolved. At the time of the report, DIZZINESS (Dizziness), INFLUENZA LIKE ILLNESS (Flu-like symptoms) and ILLNESS (Got super sick) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
This spontaneous report was received from a Physician assistant concerning an 11 year old male patient with slightly overweight. Within the last week on approximately 22-APR-2013 the patient was vaccinated in one arm with GARDASIL (Lot # not provided), 0.5 ml, intramuscular. On the same date (approximately on 22-APR-2013), the patient was also vaccinated in the other arm with ADACEL and MENACTRA. The physician assistant reported that the patient developed redness and swelling on the arm in which he received ADACEL and MENACTRA (approximately on 22-APR-2013). The patient was administered BENADRYL (manufacturer unknown) and ibuprofen (manufacturer unknown) as treatment for the adverse events. The outcome of redness and swelling was reported as recovered/resolved (approximately in April 2013). The patient was seen in physician assistant's office. This is one of several reports from the same source. Additional information has been requested.
testing pos (positive) for Covid 19; This is a spontaneous report from a contactable pharmacist reporting for a patient.   A patient of unspecified age and gender received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 10Mar2021 (Batch/Lot number was not reported) as a single dose for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported.  The patient tested positive for COVID 19 on 11Mar2021. The patient underwent lab tests and procedures which included rapid COVID 19 test: positive on 11Mar2021. The outcome of the event tested positive for COVID 19 was unknown.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
I have  Sebaceous Cyst on my armpit very close to the glend. The Sebaceous Cyst is at the same arm I recieved the first dose shot. It may be the Cyst developed from a trauma which in this case is the Moderna Covid-19 vaccine. I did go to a dermatologist who confirmed I have Sebaceous Cyst. Thank you
migraine, muscle aches, muscle weakness, joint aches, insomnia, nausea, diarrhea, injection site very sore and up and down the arm from it, fever over night
About 9-10 days after vaccination, which had initial arm soreness that went away, I noticed pain in my left armpit. This pain has expanded in the days since and now my left bicep hurts as well. I don?t seem to have a rash and can?t tell if I have any swelling because my upper arms are always a bit ?curvier?.
Pt received vaccines for 6 months plus seasonal flu on 2-24-16. Mom noticed localized papular, non fluid filled rash to injection sites on both legs on 2-25-16. Rash spreading from hip to knee on 2-26-16.
Chest "burning", faint wheeze left lower lobe on lung exam Treatment: Solumedrol 125 mg IM. Albuterol nebulizer 2.5mg/3mL Symptoms resolved after treatment
Patient states she had a 101.7 fever and chills after receiving her 2nd dose of COVID vaccine. After 2 days she developed a 8-10" oblong red, hot, hard spot about 1" below the injection site. Pt has not contacted a healthcare professional.
No Periods since receiving the Covid Vaccine - Moderna #1 given 4/8/21 and Moderna #2 given 5/7/21.
covid positive; covid positive; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP).  A 66-year-old male patient received BNT162b2 (BNT162B2), on 16Mar2021 as dose 1, single (Batch/Lot number: unknown), on 13Apr2021 as dose 2, single (Batch/Lot number: unknown) and on 20Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 65 years for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 31Mar2022 as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "allergic rhinitis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Aug2022, outcome "not recovered" and all described as "covid positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (15Aug2022) Negative; (19Aug2022) Positive; (Aug2022) positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 with Paxlovid from 11Aug2022 to 15Aug2022.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors, however a contributory role of the suspect drug BNT162B2 to the reported events Vaccination failure and COVID-19 cannot be ruled out.
A non-serious spontaneous case of inadvertent administration of FLUMIST to an asthmatic and cough has been received from a nurse in a 12-year-old male, subsequent to receiving FLUMIST.  The reporting nurse stated the patient was inadvertently administered FLUMIST.  The patient returned to see the physician on 15-Sep-2008 for a cough; at that time there was no wheezing, some rhonchi and other family members had upper respiratory symptoms.  The patient was treated with PREDNISONE and ZITHROMYCIN.  The patient was rechecked on 17-Sep-2008 at which time his lungs were clear and the cough had resolved.  All events resolved.
This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 24-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J006155 and expiry date 30-AUG-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
Redness, swelling, pain, and limp till 5 days. Also falliculitis pilaris like rash on left thigh only started day after injection.
Received Expired Dose of Vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine). On 25-May-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication information was given.  No Treatment medication information was given.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: BUPROPION, start date: 01Nov2020. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid from 20Jan2023 to 25Jan2023.  Clinical information : No Known allergies were reported.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This case was reported by a consumer via patient support programs and described the occurrence of injection site pain in a 42-year-old male patient who received RABAVERT. Co-suspect product included Tetanus NVS. Concurrent medical conditions included anxiety disorder, animal bite, low back pain (due to anxiousness) and multiple allergies. Concomitant products included Aspirin (Baby)) and immunoglobulins nos. On 12th July 2016, the patient received the 1st dose of RABAVERT and Tetanus vaccine. On 12th July 2016, less than a day after receiving RABAVERT and Tetanus vaccine, the patient experienced injection site pain and increased blood pressure. In July 2016, the patient experienced queasy and stress. On an unknown date, the outcome of the injection site pain and queasy were recovering/resolving and the outcome of the increased blood pressure was recovered/resolved and the outcome of the stress was unknown. The reporter considered the injection site pain to be related to RABAVERT and Tetanus vaccine. The reporter considered the queasy and increased blood pressure to be unrelated to RABAVERT and Tetanus vaccine. It was unknown if the reporter considered the stress to be related to RABAVERT and Tetanus vaccine. Additional information was provided as follows: This case was received from the healthcare provider via the vaccine patient assistance program. On Sunday, the patient was exposed to a bat that landed on his back but did not bite him. The patient received his 1st rabies vaccine in his right arm, which was sore, a tetanus vaccine in left arm which was also sore, 3 injections in left buttock area, 2 in right buttock area and another in his right thigh. The patient was not sure what all the shots were but thought that he may have got another vaccine shot in his right thigh and possibly the other shots were the immune globulin. On 12 July 2016, less than a day after receiving RABAVERT, the patient experienced injection site soreness and increased blood pressure. In July 2016, less than a week after receiving RABAVERT, the patient experienced queasiness in stomach and stress, but believed that it was just his anxiety. The patient's blood test was found to be 150/95 in the emergency room but his normal was 130/80. The patient also reported that he had lower back soreness generally and it was not worse since the vaccinations, however he felt that it was due to his anxiousness. The case did not include any product complaint.
Information has been received from a healthcare professional, concerning a patient (age and gender not specified) who was vaccinated in the deltoid or thigh, on an unknown date with a dose of GARDASIL, and experienced pain, swelling and redness at the injection site.  No further identifying patient details were available.  Additional information is not expected.
A deep purple bruise formed on my left underarm, lymph nodes swelled, tender to touch.  Took Tylenol and Benedryl each night from 3-12-2021 - 2-21-2021.  Bruise lasted until 3-21-2021.  Still tender but bruise is almost gone.
11/22/99:pt. rcvd vacc.11/30/99:Pt. dvlped fever,chills,SOB, confusion,& less responsive.12/1/99:EMS called,pt.had fever of 105 and began seizing.In hospital, pt. dxed w/ central herniation and cerebral edema.12/2/99:pt pronounced dead.
adult recv vax & a nurse co-worker devel a rash & hip pain 15MAY98;rash was similar in appearance to adult who recv vax;